Mutual of America Capital Management LLC Buys 7,777 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Mutual of America Capital Management LLC boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 302.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,348 shares of the medical research company's stock after buying an additional 7,777 shares during the period. Mutual of America Capital Management LLC's holdings in Bio-Rad Laboratories were worth $3,462,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Van ECK Associates Corp raised its holdings in shares of Bio-Rad Laboratories by 97.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company's stock valued at $436,861,000 after acquiring an additional 644,530 shares in the last quarter. Select Equity Group L.P. raised its stake in Bio-Rad Laboratories by 26.2% in the second quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company's stock valued at $177,391,000 after purchasing an additional 134,856 shares in the last quarter. First Eagle Investment Management LLC lifted its position in Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company's stock valued at $173,773,000 after purchasing an additional 634,311 shares during the last quarter. Earnest Partners LLC grew its stake in Bio-Rad Laboratories by 17.8% in the 2nd quarter. Earnest Partners LLC now owns 606,788 shares of the medical research company's stock worth $165,720,000 after buying an additional 91,882 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Bio-Rad Laboratories by 64.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company's stock worth $135,081,000 after buying an additional 193,700 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the transaction, the chief operating officer now directly owns 7,559 shares of the company's stock, valued at approximately $2,494,016.46. This represents a 28.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP James Barry sold 623 shares of the firm's stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. The trade was a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

BIO has been the subject of a number of research analyst reports. Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 price target for the company. Royal Bank of Canada raised their price objective on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $391.80.

Bio-Rad Laboratories Trading Up 2.3 %

BIO opened at $332.91 on Friday. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The business's 50-day moving average price is $340.52 and its 200-day moving average price is $315.68.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.16 by $0.85. The business had revenue of $649.70 million for the quarter, compared to analysts' expectations of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The business's quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.33 EPS. On average, analysts expect that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.